CLOSE
SITE MAP
イノベーションが
生まれる「まち」。

2019/01/10

International Pitch 1 :FibroTouch--Non-invasive Diagnosis of Liver Fibrosis and Fatty Liver

【300ピクセル】I-1 HISKY Medical.png

【300ピクセル】hisky.jpgJack Yu

Head of International Market,

Wuxi HISKY Medical Technologies Co.,Ltd.

[Summary]

Around one billion of the population has been reported with liver injuries-developed complications that also include hepatitis A, B and C infections along with other diseases. In China, there are around 280 million people suffering from various hepatitis diseases, mainly hepatitis B. Liver fibrosis is an important human health issue that results from chronic hepatic injury, which may further lead to cirrhosis and liver cancer with considerable mortality.

The fibrotic state of the liver can be treated if diagnosed at an early stage. However, the current detection methods like imaging and blood tests fail to do so. The golden standard for the detection of liver fibrosis is through liver biopsy, which is again not very cost-effective and is time-consuming.

Hisky Medical located in Beijing developed a medical device named FibroTouch. The machine measures three crucial aspects of liver, i.e., its stiffness in terms of KPA, liver steatosis, and morphology, by using ultrasound function. It is also called the transient elastography, which is a non-invasive technique. A low-frequency shear wave is sent to the liver followed by ultrasound waves to capture the shear wave. The speed of the shear wave traveling through the liver organs determines the stiffness.

Now, Hisky Medical looks forward to new collaborations and potential market for promoting their non-invasive product, in benefit of the mass.

[Mentors' comments]

 "Very nice presentation, thank you. Could you explain more about what kind additional value provided by this technology compared with the conventional ultrasound?"Dr. Toshio Fujimoto, Takeda Pharmaceutical Company

 "What are your intended of use by the approval? So you mentioned the three, right? The screening, prevention, and treatment.Because those three will require different clinical evidence to prove. So how do you do that?"Dr. Dan Wang, Johnson & Johnson Innovation


[Profile]

Dr. Jack Yu has a PhD and EMBA degree from Europe and has been working in the marketing & sales in major European pharmaceutical companies and medical device companies.